Daniel Dawson, MD
Family Medicine · Wilmington, NCNPI 1598993107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Teva Pharmaceuticals USA, Inc. accounts for 95.2% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $174 and has fallen 71.1% since, to $50 in 2024.
Across 40 payments — averaging $9.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$358
- Shield Therapeutics Inc$18
What the payments were for
- Food & beverage$376100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 39 | $358 |
| Shield Therapeutics Inc | 1 | $18 |
How this compares
$376 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $191,924 |
| EliquisApixaban | 64 | $92,350 |
| JardianceEmpagliflozin | 72 | $82,882 |
| TrulicityDulaglutide | 35 | $56,601 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $47,484 |
| MounjaroTirzepatide | 33 | $38,627 |
| WegovySemaglutide | 17 | $22,415 |
| MyrbetriqMirabegron | 19 | $21,372 |
| JanuviaSitagliptin Phosphate | 12 | $18,776 |
| XareltoRivaroxaban | 11 | $18,054 |
| Atorvastatin Calcium | 964 | $10,445 |
| Famotidine | 83 | $6,369 |
| Losartan Potassium | 550 | $5,931 |
| Metoprolol Succinate | 324 | $5,285 |
| Levothyroxine Sodium | 378 | $5,222 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Wilmington
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.